BSE Live
Dec 23, 16:01Prev. Close
1283.85
Open Price
1286.50
Bid Price (Qty.)
1283.00 (1)
Offer Price (Qty.)
1285.00 (497)
NSE Live
Dec 23, 15:57Prev. Close
1283.40
Open Price
1288.60
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
1283.50 (681)
| Cash Flow of Dr Reddys Laboratories (in Rs. Cr.) | Mar 05 | |
| 12 mths | ||
| Net Profit/Loss Before Extraordinary Items And Tax | 13.85 | |
| Net CashFlow From Operating Activities | 229.91 | |
| Net Cash Used In Investing Activities | 93.85 | |
| Net Cash Used From Financing Activities | 157.85 | |
| Foreign Exchange Gains / Losses | 0.00 | |
| Adjustments On Amalgamation Merger Demerger Others | 0.00 | |
| Net Inc/Dec In Cash And Cash Equivalents | 481.62 | |
| Cash And Cash Equivalents Begin of Year | 453.88 | |
| Cash And Cash Equivalents End Of Year | 935.50 |
15.12.2025
12.12.2025
25.11.2025
11.11.2025
28.10.2025
Dr Reddys Labs Consolidated September 2025 Net Sales at Rs 8,828.30 crore, up 9.83% Y-o-Y
28.10.2025
Dr Reddys Labs Standalone September 2025 Net Sales at Rs 4,618.60 crore, down 31.03% Y-o-Y
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
24.07.2025
Dr Reddys Labs Standalone June 2025 Net Sales at Rs 7,809.50 crore, up 33.7% Y-o-Y
22.01.2025
Dr Reddy's Labs Q3 Preview: Lower Revlimid contribution, subdued US sales to dent earnings growth
12.07.2023
Dr Reddys Laboratories Q1 PAT seen up 73.7% YoY to Rs 912.4 cr: Nirmal Bang
24.01.2023
Dr Reddy’s Q3 Preview | Sharp drop in net profit likely on slump in US revenues
27.10.2022
Dr Reddy’s Q2 preview: Pharma major likely to report sharp drop in net profit on weak US biz